Pharmacoeconomics of dementia

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 5, 1997, Pages

  Whitehouse, Peter J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Alzheimer disease; Cognitive impairment; Dementia; Pharmacoeconomics; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; CAREGIVER; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NOMENCLATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

ALZHEIMER DISEASE; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III; COGNITION DISORDERS; COSTS AND COST ANALYSIS; DRUG APPROVAL; ECONOMICS, PHARMACEUTICAL; FAMILY HEALTH; GUIDELINES; HUMANS; MODELS, ECONOMIC; NOOTROPIC AGENTS; QUALITY OF LIFE; RESEARCH DESIGN; TACRINE;

EID: 0030787170     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Acquardro C, Jambon B, Ellis D, Marquis P. Language and translation issues. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:575-84.
2. Albert SM, Castillo-Castaneda CD, Sano M, et al. Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Am Geriatr Soc 1996;44:1342-7.
3. Anderson RT, Aaronson NK, Leplege AP, Wilkin D. International use and application of generic health-related quality of life instrument. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:613-30.
4. Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee (including submissions involving economic analysis). Canberra, Australia, August 1992.
5. Beck C. Observable display of affect (unpublished, 1996).
6. Berzon RA, Mauskopf JA, Simeon GP. Choosing a health profile (descriptive) and/or a patient-preference (utility) measure for a clinical trial. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:375-8.
7. Blau TH. Quality of life, social indicators, and criteria of change. Professional Psychol 1977;11:464-73.
8. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney Books, 1996.
9. Brock D. Quality of life measures in health care and medical ethics. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:497-509.
10. Brod M, Stewart. Self-rated Brod/Stewart Quality of Life Instrument. Presented at the Gerontological Society of America 49th Annual Scientific Meeting, November 17-21, 1996, Washington, DC.
11. Calman KC. Quality of life in cancer patients - an hypothesis. J Med Ethics 1984;10:124-7.
12. Cavallo MS, Fattore G. The economic and social burden of Alzheimer's disease on families in Lombardy region. Italy. Alzheimer Dis Assoc Disord (in press).
13. Drummond M. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang? Pharmacoeconomics 1991(suppl 1):61-9.
14. Ernst RL, Hay JW. The U.S. economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-4.
15. Feeney DH, Torrance GW, Labelle R. Integrating economic evaluations and quality of life assessments. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:85-94.
16. Fox PJ. Service use and cost outcomes of caring for persons with Alzheimer's disease: developing new approaches to old problems. Alzheimer Dis Assoc Disord (in press).
17. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med 1996;335:331-6.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health 1987;84:1169-75.
20. Hay JW, Ernst RL. Economic research on Alzheimer's disease: A review of the literature. Alzheimer Dis Assoc Disorders (in press).
21. Henke CJ. Unpublished observations from Alzheimer's Association Annual Update XI Alzheimer's Care Management Conference "Current Research in Alzheimer's Disease: From Scientific Data to Clinically Useful Knowledge," June 11, 1996, Minneapolis, MN.
22. Henke CJ, Burchmore MJ. The economic impact of the tacrine in the treatment of Alzheimer's disease. Clin Ther 1997;19:330-45.
23. Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1987;26: 158-63.
24. Huang L, Cartwright WS, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988;103:3-7.
25. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Geriatr Soc 1994;271:985-91.
26. Knopman D, Schneider L, Davis K, et al., and the Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Am Acad Neurol 1996;47:166-77.
27. Lawton MP. Assessing quality of life. Alzheimer Dis Assoc Disord (in press).
28. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Federal Food and Drug Administration: First draft, November 8, 1990.
29. Logsdon RG. Assessment of quality of life, pleasant events, and depression in Alzheimer's disease outpatients [Abstract]. Presented at Quality of Life in Alzheimer's Disease: Implications for Research Symposium. Seattle, WA, November 20, 1996.
30. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface 1994;7:130-8.
31. Martin AJ, Lumley TS, Simes RJ. Incorporating trade-offs in quality of life assessment. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:403-11.
32. Moore MJ, Clipp EC. Alzheimer's disease and caregiver time. Lancet 1994;343:239-40.
33. Morris LA, Beckett TK, Lechter KJ. A marketing perspective: theoretical underpinnings. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. 1996:541-8.
34. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto, Ontario, Canada, 1993.
35. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto, Ontario, Canada, 1994.
36. Patterson MB, Mack JL. Cleveland Scale for Activities of Daily Living (CSADL): a brief description. Alzheimer Dis Assoc Disord (in press).
37. Patterson M, Mack J, Geldmacher D, Whitehous P. Executive functions and Alzheimer's disease: problems and prospects. Eur J Neurol 1996;3:5-15.
38. Patterson MB, Mack JL, Neundorfer MM, Martin RJ, Smyth KA, Whitehouse PJ. Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living. Alzheimer Dis Assoc Disord 1992;6: 145-63.
39. Post SG, Whitehouse PJ. Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. J Am Geriatr Soc 1995;43:1423-9.
40. Rabins PV, Kasper JD. Measuring quality of life in dementia: conceptual and practical issues. Alzheimer Dis Assoc Disord (in press).
41. Rabins PV, Kasper J, Kleinman L, Black B. Developing a scale to measure quality of life in persons with dementia [Abstract]. Presented at Quality of Life in Alzheimer's Disease: Implications for Research Symposium. Seattle, WA, November 20, 1996.
42. Rice DP, Fox W, Max P, et al. The economic burden of caring for people with Alzheimer's disease. Health Affairs 1993;12:164-76.
43. Rodwin MA. Medicine, money, and morals: physicians' conflicts of interest. New York: Oxford University Press, 1993.
44. Rogers S. Unpublished observations from the International Working Group for Harmonization of Dementia Drug Guidelines Symposium at the Fifth International Conference on Alzheimer's Disease and Related Disorders. Osaka, Japan, July 24, 1996.
45. Sano M, Ernesto C, Klauber MR, et al., and Members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 1996;10:132-40.
46. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline and alpha-tocopherol or both as treatment of Alzheimer's disease. N Engl J Med 1997;336:1216-22.
47. Spilker B. Adopting higher standards for quality of life trials. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. 1996:57-8.
48. Stuckey JC, Neundorfer MM, Smith KA. Burden and well-being: the same coin or related currency? Gerontologist 1996;36:686-93.
49. Szabo S (on behalf of the WHOQOL Group). The World Health Organization Quality of Life (WHOQOL) Assessment Instrument. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:355-62.
50. Teri L. Methodologic issues in the assessment of quality of life of Alzheimer's disease patients [Abstract]. Presented at Quality of Life in Alzheimer's Disease: Implications for Research Symposium. Seattle, WA, November 20, 1996.
51. Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:1105-11.
52. U.S. Department of Health and Human Services. Alzheimer's disease and related dementias: acute and long-term care services 1996 - a report to Congress of the Advisory Panel on Alzheimer's Disease, February, 1996.
53. Ware JE Jr. Conceptualizing disease impact and treatment outcomes. Cancer 1984;53:2316-23.
54. Warshaw G. Defining and measuring outcomes in Alzheimer's research. Alzheimer Dis Assoc Disord (in press).
55. Whitehouse PJ. Quality of life: a conceptual framework [Abstract]. Presented at Quality of Life in Alzheimer's Disease: Implications for Research Symposium. Seattle, WA, November 20, 1996.
56. Whitehouse PJ. International Working Group for Harmonization of Dementia Drug Guidelines summary report. Alzheimer Dis Assoc Disord (in press).
57. Whitehouse PJ, Rabins PV. Quality of life and dementia. Alzheimer Dis Assoc Disord 1992;6:135-7.
58. Whitehouse PJ, Orgogozo J-M, Becker RE, et al. Quality of life assessment: role in dementia drug development. Alzheimer Dis Assoc Disord (in press).
59. WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9.
60. Winblad B, Hill S, Beermann B, et al. Issues in the economic evaluation of treatment for dementia. Alzheimer Dis Assoc Disord (in press).